FDA OKs aducanumab for Alzheimer's, turning controversial Biogen drug into a megablockbuster

Jason Mast

Editor

The FDA has approved the Biogen drug aducanumab for Alzheimer’s, a stunning decision that caps nearly two years of controversy and hands the large biotech …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

FDA OKs aducanumab for Alzheimer's, turning controversial Biogen drug into a megablockbuster

Jason Mast

Editor

Sign up to read this article for free.

Drugmakers see a substantial, but manageable, hit to business from tariffs. But the worst may lie ahead

Bristol Myers CEO signals dealmaking will be a top priority in 2025

Roche CEO warns that tariffs could impact dealmaking

Roche takes steps to protect itself from tariffs, while Sanofi hangs back

Sanofi's Altuviiio closing in on blockbuster status, Dupixent sales surge

ADSTILADRIN® (nadofaragene firadenovec-vncg) – A Growing Body of Clinical Data and Real-World Evidence

FDA OKs ad­u­canum­ab for Alzheimer's, turn­ing con­tro­ver­sial Bio­gen drug in­to a megablock­buster

Jason Mast

Editor

Sign up to read this article for free.

Drug­mak­ers see a sub­stan­tial, but man­age­able, hit to busi­ness from tar­iffs. But the worst may lie ahead

Bris­tol My­ers CEO sig­nals deal­mak­ing will be a top pri­or­i­ty in 2025

Roche CEO warns that tar­iffs could im­pact deal­mak­ing

Roche takes steps to pro­tect it­self from tar­iffs, while Sanofi hangs back

Sanofi's Al­tuvi­i­io clos­ing in on block­buster sta­tus, Dupix­ent sales surge

AD­STI­LADRIN® (nad­o­fara­gene fi­rade­n­ovec-vncg) – A Grow­ing Body of Clin­i­cal Da­ta and Re­al-World Ev­i­dence

FDA OKs aducanumab for Alzheimer's, turning controversial Biogen drug into a megablockbuster

Drugmakers see a substantial, but manageable, hit to business from tariffs. But the worst may lie ahead

Bristol Myers CEO signals dealmaking will be a top priority in 2025

Roche CEO warns that tariffs could impact dealmaking

Roche takes steps to protect itself from tariffs, while Sanofi hangs back

Sanofi's Altuviiio closing in on blockbuster status, Dupixent sales surge

ADSTILADRIN® (nadofaragene firadenovec-vncg) – A Growing Body of Clinical Data and Real-World Evidence